NASDAQ:NVCN - Neovasc Stock Price, Price Target & More

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

Neovasc Inc. (NASDAQ:NVCN) released its quarterly earnings data on Wednesday, March, 28th. The medical equipment provider reported ($0.02) earnings per share for the quarter, missing the consensus estimate of ($0.01) by $0.01. The medical equipment provider earned $1.23 million during the quarter, compared to analysts' expectations of $1.18 million. Neovasc had a negative return on equity of 85.81% and a negative net margin of 1,687.90%. View Neovasc's Earnings History.

Neovasc is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Neovasc.

2 Wall Street analysts have issued 12 month target prices for Neovasc's stock. Their forecasts range from $0.50 to $2.00. On average, they expect Neovasc's share price to reach $1.25 in the next year. View Analyst Ratings for Neovasc.

Neovasc saw a increase in short interest during the month of April. As of April 30th, there was short interest totalling 74,020,430 shares, an increase of 55.3% from the April 13th total of 47,655,636 shares. Based on an average daily trading volume, of 87,826,510 shares, the days-to-cover ratio is currently 0.8 days. Approximately 83.5% of the company's stock are short sold.

Some companies that are related to Neovasc include IRadimed (IRMD), SeaSpine (SPNE), Apollo Endosurgery (APEN), Restoration Robotics (HAIR), Alphatec (ATEC), Sensus Healthcare (SRTS), INVO Bioscience (IVOB), Motus GI (MOTS), Invuity (IVTY), SANUWAVE (SNWV), Arch Therapeutics (ARTH), iCAD (ICAD), Spectral Medical (EDTXF), Repro-Med Systems (REPR) and CAS Medical Systems (CASM).

News articles about NVCN stock have trended somewhat negative on Tuesday, according to Accern. Accern identifies positive and negative media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Neovasc earned a media sentiment score of -0.02 on Accern's scale. They also gave news headlines about the medical equipment provider an impact score of 47.23 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Neovasc's stock is owned by a number of of retail and institutional investors. Top institutional investors include Gagnon Securities LLC (0.35%). View Institutional Ownership Trends for Neovasc.

NVCN stock was bought by a variety of institutional investors in the last quarter, including Gagnon Securities LLC. View Insider Buying and Selling for Neovasc.

Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NVCN stock can currently be purchased for approximately $0.04.

Neovasc has a market capitalization of $52.62 million and generates $5.39 million in revenue each year. The medical equipment provider earns $-22,900,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Neovasc employs 147 workers across the globe.

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, Richmond A1, V6V 2J7. The medical equipment provider can be reached via phone at 604-270-4344 or via email at [email protected]